Rating Change
Wells Fargo analysts initiated coverage on X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) with a Overweight rating on July 10, 2026.
Rating Change Wells Fargo analysts initiated coverage on X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) with a Overweight rating on July 10, 2026. Market Context X4 Pharmaceuticals, Inc.

Wells Fargo analysts initiated coverage on X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) with a Overweight rating on July 10, 2026.
X4 Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $4.34 with a market capitalization of $44.2M.
Analyst coverage from Wells Fargo provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for X4 Pharmaceuticals, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 10, 2026 | Wells Fargo | Overweight | N/A |
| Jun 02, 2026 | Leerink Partners | Outperform | N/A |
| Mar 09, 2026 | Guggenheim | Buy | N/A |
| Dec 05, 2025 | Stifel | Buy | N/A |
| Nov 10, 2025 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View XFOR Stock Page
A Overweight rating from Wells Fargo reflects the analyst's outlook on X4 Pharmaceuticals, Inc. (NASDAQ:XFOR). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the XFOR forecast page.
Current market data
NASDAQ · XFOR
$4.23
Up: +$0.06 · +1.44%
Live quote updated
Keep reading